

TargED Biopharmaceuticals announces publication in *Blood* demonstrating effectivity of its thrombolytic lead compound, Microlyse, in two experimental Acute Ischemic Stroke models

August 17, 2022

Utrecht, the Netherlands

- *Recombinant human tissue plasminogen activator (rh-tPA) is an important thrombolytic agent for treatment of acute ischemic stroke (AIS)*
- *Microlyse is non-inferior to rh-tPA when AIS is driven by fibrin-rich thrombi, but superior to rh-tPA when AIS is driven by platelet-rich thrombi*

TargED Biopharmaceuticals, an emerging biotech company focused on developing first-in-class biological drugs to improve treatment of thrombosis, today announced new data indication that its thrombolytic lead compound, Microlyse is effective in two experimental mouse models of acute ischemic stroke (AIS). These findings support broad applicability of Microlyse in ischemic stroke irrespective of the thrombus composition. The study is accepted for publication as Brief Report in the journal *Blood*. The pre-proof publication is online available at <https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2022016342/486218/>.

The development of Microlyse and its ability to degrade microvascular thrombi in an experiment mouse model of Thrombotic Thrombocytopenic Purpura (TTP) was earlier described in *Blood* in November 2021 (<https://ashpublications.org/blood/article-abstract/139/4/597/477915/>). Current publication supports TargED's notion that Microlyse holds the power to transform the therapeutic landscape for patients suffering from various forms of thrombosis.

"We're very proud to have another article to demonstrate the thrombolytic potential of Microlyse published in *Blood*", said Steven de Maat, PhD, Chief Scientific Officer of TargED Biopharmaceuticals. "Previously, we showed the ability of Microlyse to successfully dissolve microvascular thrombi in an *in vivo* experimental model of Thrombotic Thrombocytopenic Purpura. In our current study we have demonstrated that Microlyse is effective in two distinct models for acute ischemic stroke. Here, Microlyse shows improved efficacy compared to tPA, the only validated therapeutic treatment for ischemic stroke. Together, these studies further validate the potential of Microlyse as a broadly applicable thrombolytic agent, irrespective of either the thrombus composition or location. We truly believe that Microlyse has the power to transform the therapeutic landscape for patients with thrombotic indications".

About TargED Biopharmaceuticals

TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020 by Associate Professor at the Department of Clinical Chemistry and Haematology, Coen Maas, PhD, an expert in thrombosis and hemostasis, Steven de Maat, PhD, an expert in recombinant protein development and optimization, Marc van Moorsel, researcher with focus on Acute Ischemic Stroke and Kristof Vercruyssen, with more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013.

Contact: info@targedbio.com